Catalog No.
Product Name
Application
Product Information
Citations
-
DHODH inhibitor
Vidofludimus is a novel orally active and potent DHODH inhibitor. -
DHODH inhibitor
BAY-2402234 is a selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies. -
DHODH Inhibitor
DHODH-IN-33 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting potent anti-cancer activity with IC50 values of 5.22 μM in A549 cells and 3.03 μM in 5637 cells. This compound induces autophagy-dependent ferroptosis characterized by mitochondrial dysfunction, lipid peroxidation, and reactive oxygen species (ROS) accumulation, while demonstrating minimal toxicity in vivo. DHODH-IN-33 is a valuable tool for researching therapeutic strategies targeting non-small cell lung cancer and bladder cancer through the autophagy-mediated degradation of DHODH. -
DHODH Inhibitor
Olorofim is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), a crucial enzyme in the pyrimidine biosynthesis pathway. It demonstrates potent antifungal activity, particularly against Aspergillus fumigatus and other species within the Aspergillus genus. Olorofim is a valuable tool for research focused on fungal infections and the development of antifungal therapies. -
DHODH Inhibitor
Vidofludimus hemicalcium is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH) and a novel modulator of the farnesoid X receptor (FXR). This compound exhibits immunomodulatory properties, making it a valuable tool for investigating autoimmune disorders, including inflammatory bowel disease (IBD). Additionally, Vidofludimus hemicalcium is relevant for research in hepatic lipid metabolism and fatty liver disease due to its targeting of FXR. -
DHODH Inhibitor
JNJ-74856665 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting an IC50 of 0.396 nM for human DHODH. This compound disrupts pyrimidine synthesis, making it a valuable tool for studying the role of DHODH in various biological processes, including cell proliferation and immune response modulation. JNJ-74856665 has potential applications in research related to autoimmune diseases and cancer therapeutic strategies. -
DHODH Inhibitor
Lapachol is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), demonstrating significant immunosuppressive effects on lymphocytes by disrupting pyrimidine synthesis. This natural naphthoquinone exhibits antitumor properties, inhibiting DNA and RNA synthesis in neoplastic cells. Additionally, Lapachol has shown efficacy against Leishmania, suggesting its potential in parasitological research and therapeutic applications. -
DHODH Inhibitor
AG-636 is a selective and reversible inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting an IC50 value of 17 nM. This compound demonstrates significant anticancer activity, making it a valuable tool in cancer research and pharmacological studies targeting the de novo pyrimidine synthesis pathway. Its oral bioavailability further enhances its utility in preclinical and clinical studies. -
Immunomodulator/DHODH Inhibitor
Laflunimus is an immunomodulator that primarily functions as an inhibitor of dihydroorotate dehydrogenase (DHODH). This compound effectively suppresses the secretion of immunoglobulins, demonstrating IC50 values of 2.5 µM for IgM and 2 µM for IgG. Additionally, Laflunimus serves as an inhibitor of prostaglandin endoperoxide H synthases (PGHS-1 and PGHS-2), making it valuable for research applications focused on immunosuppression and inflammatory pathways. -
Potent DHODH Inhibitor
DHODH-IN-1 is a potent inhibitor of Dihydroorotate Dehydrogenase (DHODH), exhibiting an IC50 of 25 nM. By targeting the DHODH enzyme, this compound effectively disrupts the pyrimidine biosynthesis pathway, making it a valuable tool for researchers investigating cellular proliferation and metabolic regulation. Its application spans the study of autoimmune diseases, cancer research, and other conditions where modulation of pyrimidine synthesis is critical. -
DHODH Inhibitor
hDHODH-IN-5 is a potent inhibitor of human dihydroorotate dehydrogenase (DHODH), exhibiting an IC50 value of 0.91 μM. This compound has been demonstrated to induce differentiation in acute myeloid leukemia cells, highlighting its potential utility in cancer research. hDHODH-IN-5 serves as a valuable tool for investigating the role of DHODH in cellular differentiation and proliferation pathways. -
DHODH Inhibitor
DHODH-IN-14 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting an IC50 of 0.49 μM against rat liver DHODH. This hydroxyfurazan analog of A771726 demonstrates significant potential in the treatment of rheumatoid arthritis. Its inhibitory capacity on DHODH suggests applications in modulating pyrimidine synthesis, providing a valuable tool for research in autoimmune disorders and related therapeutic development. -
DHODH Inhibitor
hDHODH-IN-4 is a selective inhibitor of human dihydroorotate dehydrogenase (DHODH), exhibiting a pIC50 of 7.8 against human recombinant DHODH. This compound effectively inhibits measles virus replication, demonstrated by a pMIC50 of 8.8. As a DHODH inhibitor, hDHODH-IN-4 is valuable for research into viral infections and the modulation of pyrimidine metabolism. -
HsDHODH Inhibitor
hDHODH-IN-3 is a potent inhibitor of human dihydroorotate dehydrogenase (HsDHODH), which plays a critical role in the de novo pyrimidine synthesis pathway. This compound has demonstrated significant antiviral activity, particularly inhibiting measles virus replication with a pMIC50 value of 8.6. hDHODH-IN-3 is particularly valuable for research in virology and metabolic diseases. -
hDHODH Inhibitor
hDHODH-IN-1 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH), an enzyme essential for de novo pyrimidine synthesis. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research in autoimmune diseases and inflammatory conditions. Its mechanism of action allows for exploration in therapeutic applications aimed at modulating immune responses and cellular proliferation. -
PfDHODH Inhibitor
PfDHODH-IN-1 is an inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH). This compound exhibits significant antimalarial activity by disrupting the pyrimidine biosynthesis pathway in the malaria parasite. PfDHODH-IN-1 serves as a valuable tool for research focused on malaria treatment and the exploration of novel therapeutic strategies against Plasmodium falciparum infections. -
Rat DHODH Inhibitor
DHODH-IN-11 is a Leflunomide derivative that functions primarily as a dihydroorotate dehydrogenase (DHODH) inhibitor. This compound demonstrates weak inhibitory activity against DHODH, an essential enzyme in the de novo pyrimidine synthesis pathway. It is particularly relevant for research in cellular metabolism and immunology, providing insights into therapeutic strategies for autoimmune disorders and certain cancers. -
DHODH Inhibitor
DHODH-IN-8 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH) in both human and Plasmodium falciparum, exhibiting IC50 values of 0.13 μM and 47.4 μM, respectively. Additionally, it demonstrates Kis of 0.016 μM for human DHODH and 5.6 μM for the parasite's enzyme. This compound shows significant antimalarial activity, making it a valuable tool for research into malaria treatment and the inhibition of the pyrimidine biosynthesis pathway. -
DHODH Inhibitor
DHODH-IN-20 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), an iron-containing flavin-dependent enzyme located in the inner mitochondrial membrane of human cells. By inhibiting DHODH, this compound exhibits significant anti-tumor activity, making it a valuable tool in the study of cancer biology. DHODH-IN-20 is particularly relevant for research focused on acute myelogenous leukemia, offering insights into potential therapeutic strategies. -
HsDHODH Inhibitor
DHODH-IN-3 is a selective inhibitor of Human Dihydroorotate Dehydrogenase (HsDHODH), demonstrating a potent inhibitory effect with an IC50 value of 261 nM. By targeting the ubiquinone binding sites within the enzyme, DHODH-IN-3 exhibits a competitive inhibition profile, characterized by a Kiapp of 32 nM. This compound shows promise for therapeutic applications in malaria research, potentially contributing to the development of novel treatments. -
DHODH Inhibitor
DHODH-IN-12 is a derivative of Leflunomide that functions as a dihydroorotate dehydrogenase (DHODH) inhibitor. This compound displays weak inhibitory activity against DHODH, making it a valuable tool for studying the modulation of pyrimidine metabolism. Its applications include investigations into immunological diseases and the development of therapeutics targeting nucleotide synthesis pathways. The pKa of 5.07 further informs its solubility and stability characteristics in biological systems. -
hDHODH Inhibitor
hDHODH-IN-2 is a selective inhibitor of human dihydroorotate dehydrogenase (hDHODH), functioning as an analogue of Leflunomide's active metabolite. This compound exhibits anti-inflammatory properties, making it relevant for research into autoimmune diseases and other inflammatory conditions. Its mechanism of action targets pyrimidine synthesis, effectively reducing the production of lymphocytes involved in inflammatory responses. -
DHODH Inhibitor
DHODH-IN-13 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), displaying an IC50 of 4.3 μM for rat liver DHODH. This hydroxyfurazan analog of A771726 demonstrates significant biological activity in modulating pyrimidine metabolism. DHODH-IN-13 is primarily utilized in research related to rheumatoid arthritis and other autoimmune conditions, making it a valuable tool for exploring therapeutic strategies in these areas. -
hDHODH Inhibitor
hDHODH-IN-14 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH), exhibiting an IC50 value of 0.469 μM. This compound is utilized primarily in research focused on modulating the de novo pyrimidine biosynthesis pathway. Its inhibitory effects make hDHODH-IN-14 a valuable reagent for studying metabolic processes and potential therapeutic strategies in various diseases, including autoimmune disorders and cancer. -
DHODH Inhibitor
DHODH-IN-19 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), an essential enzyme located in the inner membrane of human mitochondria that is critical for pyrimidine biosynthesis. This compound demonstrates significant anticancer activity by inhibiting tumor growth, making it a valuable tool for research in cancer and inflammatory diseases. Its mechanism of action offers potential insights into the metabolic pathways involved in these conditions. -
DHODH Inhibitor
hDHODH-IN-7 is a selective inhibitor of human dihydroorotate dehydrogenase (DHODH). It exhibits antiviral activity with a reported pMIC50 of 7.4, indicating its potential efficacy in reducing viral replication. This compound is suitable for research applications involving the study of viral infections and the regulation of pyrimidine biosynthesis. -
DHODH Inhibitor
DHODH-IN-15 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor, exhibiting an IC50 of 11 μM in rat liver DHODH assays. This hydroxyfurazan analog of A771726 demonstrates significant biological activity, making it a valuable tool for investigating the role of DHODH in various metabolic pathways. Its application extends to research on rheumatoid arthritis, contributing to the understanding of therapeutic strategies for inflammatory diseases. -
DHODH Inhibitor
DHODH-IN-25 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC50 value of 5.4 nM for human DHODH. This compound demonstrates significant biological activity and is particularly relevant for research applications involving acute myeloid leukemia (AML). DHODH-IN-25 provides valuable insights into the therapeutic potential of targeting pyrimidine biosynthesis in cancer treatment. -
DHODH Inhibitor
DHODH-IN-4 is a dihydroorotate dehydrogenase (DHODH) inhibitor targeting both human and Plasmodium falciparum DHODH. With IC50 values of 4 μM for PfDHODH and 0.18 μM for HsDHODH, this compound demonstrates significant potential as an antimalarial agent. It is suitable for research applications focused on understanding malaria pathology and developing effective treatments against Plasmodium infections. -
DHODH Inhibitor
DHODH-IN-24 is a potent inhibitor of human dihydroorotate dehydrogenase (DHODH) with an IC50 value of 91 nM. This compound effectively impairs the proliferation of rapidly dividing cells by hindering pyrimidine synthesis. DHODH-IN-24 is an important tool for investigating the role of DHODH in various biological processes and may have applications in the research of autoimmune diseases and cancer therapy. -
DHODH Inhibitor
P1788 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine synthesis pathway. By inhibiting DHODH, P1788 induces DNA damage and has demonstrated potential in various cancer research applications. Its effects on pyrimidine metabolism make it a valuable tool for studying cellular proliferation and apoptosis. -
RORγ/DHODH Inhibitor
RORγ/DHODH-IN-1 is a dual inhibitor targeting RORγ and dihydroorotate dehydrogenase (DHODH) with IC50 values of 9.7 nM and 100 nM, respectively. This compound effectively inhibits the replication of SARS-CoV-2, human cytomegalovirus (HCMV), and adenovirus type 5 (HAdV5), making it a valuable tool in viral research. Its dual mechanism of action allows for potential applications in understanding viral-pathogen interactions and developing therapeutic strategies against viral infections. -
RORγ/DHODH Inhibitor
RORγ/DHODH-IN-2 is a potent dual inhibitor of RORγ and DHODH, exhibiting IC50 values of 11.9 nM and 90 nM, respectively. This compound demonstrates significant antiviral activity against multiple viruses, including SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC50 values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively. RORγ/DHODH-IN-2 is ideal for research applications targeting immune signaling pathways and viral infections. -
PfDHODH Inhibitor
PfDHODH-IN-3 is a potent inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC50 of 47 nM. This compound exhibits strong antimalarial activity, effectively inhibiting the growth of Plasmodium in animal models. PfDHODH-IN-3 is valuable for research focused on antimalarial drug development and understanding the mechanisms of Plasmodium resistance. -
PfDHODH Inhibitor
DSM267 is a triazolopyrimidine compound that preferentially inhibits Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC50 of 38 nM, demonstrating significant selectivity over human DHODH with an IC50 exceeding 100,000 nM. This reagent is valuable for in vitro systematic screening and characterizing the pathways of resistance evolution in Plasmodium falciparum against DHODH inhibitors. Its use supports research into antimalarial resistance mechanisms and facilitates the development of novel therapeutic strategies. -
DHODH Inhibitor
Genz-669178 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), demonstrating an IC50 range of 0.015-0.05 μM against Plasmodium species. It effectively inhibits P. berghei and P. falciparum strains 3D7 and Dd2, with respective IC50 values of 0.068, 0.008, and 0.01 μM. In vivo studies indicate that Genz-669178 exhibits significant anti-malarial efficacy in P. berghei-infected mice, with an ED50 of 13-21 mg/kg/day, alongside favorable pharmacokinetic properties. This compound serves as a valuable tool for malaria research and drug development. -
PfDHODH/PbDHODH Inhibitor
DSM74 is a potent inhibitor of dihydroorate dehydrogenase (DHODH) in both Plasmodium falciparum (PfDHODH) and Plasmodium berghei (PbDHODH), with IC50 values of 0.28 μM and 0.38 μM, respectively. This orally active compound exhibits significant antimalarial activity, effectively inhibiting the growth of Plasmodium species in animal models. It is a valuable tool for researchers investigating the mechanisms of malaria and developing novel therapeutic strategies. -
PfDHODH Inhibitor
BRD7539 is a potent inhibitor of PfDHODH, exhibiting an IC50 value of 0.033 μM. This compound demonstrates significant efficacy against multidrug-resistant asexual blood-stage Plasmodium falciparum (Dd2 strain) with an EC50 of 0.010 μM, as well as against liver-stage Plasmodium berghei, with an EC50 of 0.015 μM. BRD7539 serves as a valuable tool for research targeting malaria drug development and resistance mechanisms. -
DHODH Inhibitor
DSM502 is a pyrrole-based inhibitor targeting Dihydroorotate Dehydrogenase (DHODH). It demonstrates nanomolar potency against Plasmodium DHODH and effectively inhibits Plasmodium parasites while showing no activity against mammalian DHODHs. This selectivity makes DSM502 a valuable tool for research into malaria and other Plasmodium-related diseases. -
DHODH Inhibitor
DSM705 hydrochloride is a potent inhibitor of Dihydroorotate Dehydrogenase (DHODH), targeting the enzymatic activity essential for the de novo pyrimidine synthesis in Plasmodium species. It demonstrates high nanomolar potency against P. falciparum and P. vivax DHODH with IC50 values of 95 nM and 52 nM, respectively, while sparing mammalian DHODH enzymes. This compound is valuable for research into antimalarial therapeutics and understanding the biochemical mechanisms of Plasmodium infections. -
PfDHODH Inhibitor
PfDHODH-IN-2 is a specific inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH), exhibiting potent activity with an IC50 of 1.11 µM. This compound serves as an effective antimalarial agent, making it valuable for research focused on malaria and the development of therapeutic strategies against this disease. Its mechanism of action targets the pyrimidine biosynthesis pathway, providing a crucial approach for disrupting parasite proliferation. -
DHODH Inhibitor
DSM705 is a pyrrole-based inhibitor of Dihydroorotate Dehydrogenase (DHODH). It demonstrates nanomolar potency against Plasmodium DHODH and exhibits significant activity against Plasmodium parasites while sparing mammalian DHODHs. This compound is a potent antimalarial agent, making it a valuable tool for research in malaria treatment and related studies. -
RORγ/DHODH Inhibitor
Izumerogant (IMU-935) is an orally active dual inhibitor of RORγ and DHODH, with IC50 values of 10 nM and 98 nM, respectively. This compound effectively disrupts the replication of various viruses, including SARS-CoV-2, HCMV, and HAdV5, demonstrated by EC50 values ranging from 3.6 to 17 nM. Izumerogant serves as a valuable tool for investigating antiviral mechanisms and therapeutic strategies against viral infections. -
DHODH Inhibitor
DHODH-IN-17 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), with an IC50 value of 0.40 μM. This compound is pivotal for studying the metabolic pathways involved in acute myeloid leukemia (AML) and may aid in the development of targeted therapies for this condition. Its ability to inhibit DHODH highlights its potential use in cancer research, particularly in understanding tumor metabolism and proliferation. -
DHODH Inhibitor
DHODH-IN-23 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine synthesis pathway. This compound exhibits significant biological activity in cancer research, facilitating the exploration of metabolic pathways and their implications in tumorigenesis. DHODH-IN-23 serves as a valuable tool for studies aiming to elucidate the role of pyrimidine metabolism in cancer cell proliferation and survival. -
hDHODH Inhibitor
hDHODH-IN-13 is an inhibitor of human dihydroorotate dehydrogenase (hDHODH), with an IC50 value of 173.4 nM. This compound demonstrates significant potential in the investigation of inflammatory bowel disease (IBD) by modulating pyrimidine biosynthesis. hDHODH-IN-13 is a valuable tool for exploring therapeutic strategies targeting hDHODH in various disease models.
